Table 2 Summary of adverse events
Adverse events | Grade 1 or 2 | Grade ≥ 3 |
|---|---|---|
Number of patients (percent) | ||
Hematological toxicity | ||
Neutropenia | 4 (7.4) | 0 |
Nonhematological toxicity | ||
Neuropathy: sensory | 9 (16.7) | 2 (3.7) |
Neuropathy: motor | 2 (3.7) | 0 |
Hyperglycemia | 2 (3.7) | 0 |
Obesity | 1 (1.9) | 0 |
Cushingoid | 1 (1.9) | 0 |
Constipation | 3 (5.6) | 0 |
Alanine/aspartate aminotransferase increased | 2 (3.7) | 0 |
Deep venous thromboembolism | 1 (1.9) | 0 |
Creatinine | 0 | 1 (1.9) |
Arthralgia | 0 | 1 (1.9) |
Osteoporosis | 2 (3.7) | 0 |
Photophobia | 1 (1.9) | 0 |
Fatigue | 2 (3.7) | 0 |
Erectile dysfunction | 1 (1.9) | 0 |
